Table 1

Comparison of the methods used to investigate mutant fHbp vaccines in studies using transgenic mice

ParameterValue(s) for each mutant fHbp vaccine (reference)a
Recombinant fHbp (47)NOMV (46)Recombinant fHbp (48)
Vaccine dose (μg of protein)202.520
AntigenfHbp R41S-His6NOMV expressing fHbp R41SfHbp E218A/E239A, R41A, and I246A (each with His6)
AdjuvantAluminum hydroxideAluminum hydroxideAluminum hydroxide
No. of doses of vaccine (route)3 (i.p.)3 (i.p.)3 (i.p.)
Bactericidal group B target strainH44/76 (fHbp ID 1; PorA VR type 7,16)Cu385 (fHbp ID 1; PorA VR type 19,15)MC58 (fHbp ID 1; PorA VR type 7,16-2)
Mouse genetic backgroundBALB/cBALB/cC57BL/6
Age at immunization (mo)1.5 to 22 to 43 to 4
SexMales and femalesMales and femalesNot reported
Mouse fHPresentPresentAbsent
Transgenic fHFull-length human fHFull-length human fHChimeric mouse-human fHb
Enhancer/promoterCMV/chicken β-actinCMV/chicken β-actinNone/apoE
Serum human or chimeric fH (mean [range]) (μg/ml)268 (89 to 610)427c (249 to 788)Not reportedd
  • a All three studies used WT fHbp ID 1 in variant group 1 for preparing the mutant and control fHbp vaccines. The amino acid residues in the mutants are numbered based on the mature fHbp ID 1 protein sequence (http://pubmlst.org/neisseria/fHbp). i.p., intraperitoneal.

  • b The chimeric fH molecule consisted of human short consensus repeat domains (SCRs) 6 to 8 flanked by the mouse sequences for SCRs 1 to 5 and SCRs 9 to 20.

  • c Only mice that expressed levels of human fH of >240 μg/ml were selected for use in this study.

  • d The serum concentrations of the chimeric fH in the transgenic mouse line were reported in a previous publication to be between 92 and 210 μg/ml (55).